Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a blood filter sweep out hidden plastic pollution?

NCT ID NCT07658443

Knowledge-focused Sponsor: Proxima Health, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This study investigates whether a medical procedure called double-filtration plasmapheresis (DFPP) can reduce the amount of tiny plastic particles circulating in human blood. Twenty adults who are already scheduled to receive DFPP for other medical reasons will provide blood samples before and after treatment. Researchers will measure changes in microplastic and nanoplastic levels using advanced lab techniques. The goal is to see if this filtering method can effectively remove plastic particles from the bloodstream.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Double-filtration plasmapheresis (DFPP) using the IN300 Inuspheresis device
What this could lead to
If successful, this could show that plasmapheresis reduces plastic particle levels in blood, potentially pointing toward a method to lower body plastic burden.
What could go wrong
This is a small, early observational study with only 20 participants. It measures short-term changes, not long-term health effects, and may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 to 80 who have already been independently prescribed and medically cleared for DFPP by a qualified treating clinic and who are willing and able to provide paired pre- and post-treatment blood samples.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years * Body weight greater than 40 kg (approximately 88 lb) * Already independently prescribed DFPP treatment by a qualified treating clinic * Able to understand the study and provide voluntary informed consent * Willing and able to provide blood samples before and after DFPP treatment * Cleared for DFPP by the prescribing clinic * Has not had plasmapheresis treatment within the past 7 days Exclusion Criteria: * Not yet prescribed DFPP by a treating clinic * Major heart or circulatory problems, such as recent myocardial infarction or hypertensive crisis * Serious kidney or liver impairment * Blood-clotting disorders or significantly impaired coagulation * Active infection, inflammation, or fever * Severe frailty or very poor medical condition * Anemia with hemoglobin below 8 g/dL * Body weight under 40 kg * Pregnancy or breastfeeding * Determined by the treating clinic to be medically or mentally inappropriate for DFPP

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Double-filtration plasmapheresis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Double-filtration plasmapheresis Microplastic and nanoplastic particle burden in peripheral blood

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ayus Medical Basel AG

    Basel, 4051, Switzerland

  • Ayus Medical Buergenstock - Buergenstock Resort Lake Lucerne

    Obergünzburg, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.